Table 2.1PICO questions for the recommendations in women (the general population of women and women living with HIV)

PICO 1Should one screen-and-treat strategy versus another screen-and-treat strategy be used in women?
PICO 2Should one screen, triage and treat strategy versus another screen, triage and treat strategy be used in women?
PICO 3, 4, 5, 6, 7Should women be followed up 12 and/or 24 months, or 3, 5 or 10 years after a negative or positive test result (and treatment) with the same or a different screening test?
PICO 8iShould women first be screened for cervical pre-cancer lesions at a specific age (or following an HIV-positive test in women living with HIV)?
PICO 8iiShould women be screened at least twice in a lifetime or once?
PICO 9Should treatment be within 6 or 12 months after a positive screening test, or after positive screen and triage tests (both positive), or after histologically confirmed cervical intraepithelial neoplasia (CIN)?
PICO 10Should there be different treatments for women with histologically confirmed CIN 2/3 (including carcinoma in situ) or adenocarcinoma in situ (AIS)?
PICO 11aWhat are the effects of health-system interventions to enable the adoption, implementation and scale-up of effective screening approaches?
PICO 12aWhat are the effects of patient-targeted strategies to support uptake of screening approaches and follow-up care?
PICO 13aWhat are the effects of provider-targeted strategies to support the adoption of screening approaches and follow-up care?
a

Next phase of guideline development (Phase 3).

From: 2, Methods

Cover of WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention
WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention [Internet]. 2nd edition.
© World Health Organization 2021.

Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”.

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (http://www.wipo.int/amc/en/mediation/rules/).

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.